Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2026 | $18.00 | Neutral → Buy | UBS |
| 1/16/2026 | $15.00 | Hold → Buy | Argus |
| 12/9/2025 | $15.00 | Overweight | Barclays |
| 10/15/2025 | $15.00 | Buy | Truist |
| 6/6/2025 | $10.00 | Neutral | Goldman |
| 7/19/2024 | $15.00 | Buy | Jefferies |
| 10/23/2023 | $13.00 → $9.00 | Neutral → Underperform | BofA Securities |
| 6/23/2023 | $11.00 | Equal Weight → Underweight | Barclays |
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
FDA PDUFA Goal Date Set for Dec. 27, 2026PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026. Acute pain affects more than 80 million individuals in the United States each year, where opioids remain a commonly used treatment option.1,2 "FDA's acceptance of
PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m. ET.Investors and the general public are invited to listen to the live webcast of the event at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients
Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in JapanContinues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026Reaffirms 2026 Financial Guidance [1]PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced its fi
UBS upgraded Viatris from Neutral to Buy and set a new price target of $18.00
Argus upgraded Viatris from Hold to Buy and set a new price target of $15.00
Barclays initiated coverage of Viatris with a rating of Overweight and set a new price target of $15.00
8-K - Viatris Inc (0001792044) (Filer)
10-Q - Viatris Inc (0001792044) (Filer)
8-K - Viatris Inc (0001792044) (Filer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in JapanContinues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026Reaffirms 2026 Financial Guidance [1]PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced its fi
PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026.About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed
Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFOPITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity.Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor. Mistras will remain with the Company until May 22, 2026, to facilitate a seamless transition."We thank Doretta for her significant contributions, which have helped prepare the Company
Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition
PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies. Ramsburg is an accomplished leader with more than 25 years of experience building and leading highly effective cross-functional
PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)